Welcome. I see you got here 3 days ago.
You exhibit an uncanny amount of similarity to another recently banned user. Even the "you believe it" slur is someone else's line.
Let start with your by addressing your intellectual integrity.
Please point out anything to do with "toxic metals" that I've ever brought up.
Of course you cannot, since that's a baseless criticism of me intended to discredit perfectly valid points I've made regarding other issues of harm reduction some would rather not hear.
Thats a pattern going back nearly 2 decades here at Meso.
Similar vicious ad hominem attacks were made on those asserting .22 micron filters were a good idea before it became the norm.
There's even a published study of home brewers that observes the contrast between the majority asserting they do it for reasons of safety, vs UGLs, yet respond with hostility and rationalizations when lapses are pointed out in their methods and improvements suggested.
Your entire argument is so weak and flawed I doubt you'd find anyone swayed by it, even if only instinctively.
Quoting random financials from two uniquely successful pharma companies represents nearly nothing regarding trends.
Perhaps you should look at what affects the hundreds of companies in this industry to get a more compete picture?
Innovation in pharma is on the decline.
Costs are rising in relation to returns.
Generally the low hanging fruit was picked long ago, leaving invocation to the more complex drugs, but also the ever tightening regulatory state, along with increasingly large losses from litigation are making the risk to reward ratio less attractive.
Couple that with the recent legislation targeting "Big Pharma", and the fact pharma development generally stretches out many years, if not decades, so with that much advance planning changes are slow to manifest. Like turning a giant ship.
Yet the slowdown is manifesting, clearly observed by people smarter than you, and alarm bells have been ringing within the R&D community for over a year.
Educate yourself, and don't forget not to let your VPN drop. Meso's forum software is very good at detecting alt accounts.
Many promising small molecules have lost significant investment appeal as a result of lopsided incentives favoring biologics in 2022’s Inflation Reduction Act.
www.biospace.com
A report published by the US Food and Drug Administration (FDA) in 2019 titled 'Drug shortages; Root Causes and Potential Solutions?' identified the lack ofincentives for manufacturers to produce less profitable drugs as one of the root causes of drug shortages.
www.clinicaltrialsarena.com
Our latest report looks at the current state of R&D returns for 20 leading biopharma companies; how to streamline clinical trials, optimize pipeline value, and leverage AI and analytics to boost productivity and ROI.
www2.deloitte.com
America’s leadership in advanced-technology industries can never be taken for granted, as evidenced by its losses in telecommunications equipment, semiconductors, televisions, solar panels, and chemicals. Policymakers must recognize what went wrong in those cases to avoid a similar industrial...
itif.org
And by the way. If you're genuinely a new user (*cough*), "Harm Reduction" means putting in a genuine effort to contribute, if not novel ideas, decent, respectful discussion, not simply finding a target to attack.